[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT3214081T - Derivado de isoindolina, seu intermediário, seu método de preparação, sua composição farmacêutica e sua utilização - Google Patents

Derivado de isoindolina, seu intermediário, seu método de preparação, sua composição farmacêutica e sua utilização

Info

Publication number
PT3214081T
PT3214081T PT158559864T PT15855986T PT3214081T PT 3214081 T PT3214081 T PT 3214081T PT 158559864 T PT158559864 T PT 158559864T PT 15855986 T PT15855986 T PT 15855986T PT 3214081 T PT3214081 T PT 3214081T
Authority
PT
Portugal
Prior art keywords
preparation
pharmaceutical composition
isoindoline derivative
isoindoline
derivative
Prior art date
Application number
PT158559864T
Other languages
English (en)
Original Assignee
Kangpu Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kangpu Biopharmaceuticals Ltd filed Critical Kangpu Biopharmaceuticals Ltd
Publication of PT3214081T publication Critical patent/PT3214081T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT158559864T 2014-10-30 2015-08-27 Derivado de isoindolina, seu intermediário, seu método de preparação, sua composição farmacêutica e sua utilização PT3214081T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410605148 2014-10-30
CN201410632870 2014-11-11

Publications (1)

Publication Number Publication Date
PT3214081T true PT3214081T (pt) 2020-08-31

Family

ID=55856570

Family Applications (2)

Application Number Title Priority Date Filing Date
PT158559864T PT3214081T (pt) 2014-10-30 2015-08-27 Derivado de isoindolina, seu intermediário, seu método de preparação, sua composição farmacêutica e sua utilização
PT192144723T PT3643709T (pt) 2014-10-30 2015-08-27 Derivado, intermediário, método de preparação, composição farmacêutica de isoindolina e utilização dos mesmos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT192144723T PT3643709T (pt) 2014-10-30 2015-08-27 Derivado, intermediário, método de preparação, composição farmacêutica de isoindolina e utilização dos mesmos

Country Status (15)

Country Link
US (1) US10017492B2 (pt)
EP (2) EP3643709B1 (pt)
JP (1) JP6546997B2 (pt)
KR (1) KR102191256B1 (pt)
CN (2) CN111205268B (pt)
AU (1) AU2015341301B2 (pt)
CA (1) CA2966038C (pt)
CY (1) CY1123361T1 (pt)
DK (2) DK3214081T3 (pt)
ES (2) ES2812877T3 (pt)
NZ (1) NZ731789A (pt)
PL (2) PL3214081T3 (pt)
PT (2) PT3214081T (pt)
RU (1) RU2695521C9 (pt)
WO (1) WO2016065980A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3202461B1 (en) 2010-02-11 2018-12-26 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
PT3214081T (pt) 2014-10-30 2020-08-31 Kangpu Biopharmaceuticals Ltd Derivado de isoindolina, seu intermediário, seu método de preparação, sua composição farmacêutica e sua utilização
NZ742001A (en) * 2015-09-29 2019-06-28 Kangpu Biopharmaceuticals Ltd Pharmaceutical composition and application thereof comprising a benzoheterocyclic compound
US10759808B2 (en) * 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN105968133B (zh) * 2016-05-18 2018-09-21 大连和田科技有限公司 一种磷酸酯季铵盐杀菌剂的制备方法
WO2018001270A1 (en) * 2016-06-30 2018-01-04 Noratech Pharmaceuticals, Inc. Palbociclib prodrugs and composition thereof
WO2018010142A1 (en) 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
JP7048106B2 (ja) * 2016-12-16 2022-04-05 カンプ・バイオファーマスーティカルズ、リミテッド 組み合わせ、その用途及び処置方法
PL3581182T3 (pl) * 2017-02-13 2022-01-17 Kangpu Biopharmaceuticals, Ltd. Kombinacja lecząca nowotwór złośliwy gruczołu krokowego, kompozycja farmaceutyczna i sposób leczenia
CN108929307A (zh) * 2017-05-22 2018-12-04 苏州偶领生物医药有限公司 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
JP6737967B1 (ja) * 2017-07-18 2020-08-12 ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ ５−フルオロ−２−メチル−３−ニトロ安息香酸およびそのメチルエステルを製造する方法
CA3072735A1 (en) 2017-08-21 2019-02-28 Celgene Corporation Processes for the preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate
US10513515B2 (en) * 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
AR114803A1 (es) * 2018-04-23 2020-10-14 Celgene Corp Compuestos de 4-aminoisoindolin-1,3-diona sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
BR122022012697B1 (pt) 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
CA3106239A1 (en) 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
US20220041576A1 (en) * 2018-09-30 2022-02-10 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Isoindoline compound, preparation method, pharmaceutical composition and use thereof
AU2019381688A1 (en) * 2018-11-13 2021-06-03 Biotheryx, Inc. Substituted isoindolinones
US20220041578A1 (en) 2018-12-06 2022-02-10 Shanghai Institute Of Meteria Medica, Chinese Academy Of Sciences Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound
CN109776377B (zh) * 2019-02-01 2021-08-24 沈阳药科大学 吲哚啉类化合物及其制备方法和应用
AR119715A1 (es) 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
ES2967929T3 (es) * 2019-10-21 2024-05-06 Celgene Corp Métodos de tratamiento de neoplasias hematológicas mediante 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolina-1,3-diona
WO2021136461A1 (zh) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的应用
JP7408819B2 (ja) * 2020-01-20 2024-01-05 カング バイオファーマシューティカルズ リミテッド イソインドリン誘導体、並びにその医薬組成物及び使用
WO2021170021A1 (zh) * 2020-02-25 2021-09-02 上海科技大学 基于戊二酰亚胺骨架的化合物及其应用
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
WO2021219078A1 (zh) * 2020-04-30 2021-11-04 上海科技大学 基于杂环和戊二酰亚胺骨架的化合物及其应用
CN113896711A (zh) * 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 杂环类免疫调节剂
EP4277901A1 (en) 2021-01-13 2023-11-22 Monte Rosa Therapeutics, Inc. Isoindolinone compounds
WO2024027694A1 (zh) * 2022-08-01 2024-02-08 苏州开拓药业股份有限公司 一种蛋白降解剂
CN118019736A (zh) * 2022-09-08 2024-05-10 标新生物医药科技(上海)有限公司 基于cereblon蛋白设计的分子胶化合物及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678500A (en) 1984-06-29 1987-07-07 E. I. Du Pont De Nemours And Company Herbicidal 2,6-disubstituted benzylsulfonamides and benzenesulfamates
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
CZ302378B6 (cs) * 1996-07-24 2011-04-20 Celgene Corporation Optický izomer (S)-1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindolin a farmaceutická kompozice s jeho obsahem
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
EP1423115B9 (en) 2001-08-06 2009-09-02 The Children's Medical Center Corporation Antiangiogenic activity of nitrogen substituted thalidomide analogs
TW200404054A (en) 2002-07-26 2004-03-16 Wako Pure Chem Ind Ltd Method for deuteration of aromatic ring
WO2005028436A2 (en) 2003-09-17 2005-03-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Thalidomide analogs as tnf-alpha modulators
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
ES2437592T3 (es) 2004-09-03 2014-01-13 Celgene Corporation Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
CA2620085C (en) * 2005-08-31 2016-07-12 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
RU2009114159A (ru) * 2006-09-15 2010-10-20 Селджин Корпорейшн (Us) N-метиламинометилизоидольные соединения, композиции, включающие их, и способы их применения
NZ599199A (en) * 2007-03-20 2013-10-25 Celgene Corp 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
US8288414B2 (en) 2007-09-12 2012-10-16 Deuteria Pharmaceuticals, Inc. Deuterium-enriched lenalidomide
UA107783C2 (en) 2008-10-29 2015-02-25 Celgene Corp Isoindoline compounds for use in treating cancer
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
BRPI0915267A2 (pt) 2008-11-14 2015-08-18 Concert Pharmaceuticals Inc Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição
EP2396312A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
CN101580501B (zh) 2009-06-01 2011-03-09 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
EP3090999A1 (en) * 2009-06-18 2016-11-09 Concert Pharmaceuticals Inc. Deuterated isoindoline-1, 3-dione derivatives as pde4 and tnf-alpha inhibitors
JP2013512195A (ja) * 2009-11-24 2013-04-11 セルジーン コーポレイション ビタミンｄ耐性腫瘍細胞においてビタミンｄ感受性を回復させるための免疫調節性化合物
EP3202461B1 (en) * 2010-02-11 2018-12-26 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
EP2582836B1 (en) 2010-06-18 2018-03-07 Taiho Pharmaceutical Co., Ltd. Prpk-tprkb modulators and uses thereof
AU2011329619A1 (en) 2010-11-18 2013-05-02 Deuteria Pharmaceuticals, Inc. 3-deutero-pomalidomide
WO2012079022A1 (en) * 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
WO2014180882A2 (en) 2013-05-07 2014-11-13 Universitat De Barcelona Treatment of brain metastasis from cancer
PT3214081T (pt) 2014-10-30 2020-08-31 Kangpu Biopharmaceuticals Ltd Derivado de isoindolina, seu intermediário, seu método de preparação, sua composição farmacêutica e sua utilização

Also Published As

Publication number Publication date
RU2017118453A3 (pt) 2019-01-17
CY1123361T1 (el) 2021-12-31
WO2016065980A1 (zh) 2016-05-06
RU2695521C2 (ru) 2019-07-23
CN111205268A (zh) 2020-05-29
RU2695521C9 (ru) 2019-08-19
JP6546997B2 (ja) 2019-07-17
ES2812877T3 (es) 2021-03-18
CN105566290B (zh) 2020-05-22
EP3643709A1 (en) 2020-04-29
KR20170078740A (ko) 2017-07-07
PL3643709T3 (pl) 2022-02-21
CN105566290A (zh) 2016-05-11
CN111205268B (zh) 2021-01-26
DK3643709T3 (da) 2021-12-20
CA2966038A1 (en) 2016-05-06
EP3214081B1 (en) 2020-07-08
US10017492B2 (en) 2018-07-10
CA2966038C (en) 2020-04-21
JP2017533955A (ja) 2017-11-16
EP3214081A4 (en) 2018-08-15
EP3643709B1 (en) 2021-10-20
DK3214081T3 (da) 2020-09-28
AU2015341301A1 (en) 2017-06-01
PL3214081T3 (pl) 2021-04-06
EP3214081A1 (en) 2017-09-06
ES2901509T3 (es) 2022-03-22
US20170313676A1 (en) 2017-11-02
NZ731789A (en) 2019-04-26
PT3643709T (pt) 2021-12-20
AU2015341301B2 (en) 2019-05-16
KR102191256B1 (ko) 2020-12-15
RU2017118453A (ru) 2018-12-04

Similar Documents

Publication Publication Date Title
PT3643709T (pt) Derivado, intermediário, método de preparação, composição farmacêutica de isoindolina e utilização dos mesmos
HK1255566A1 (zh) 氧代吡啶酰胺類衍生物、其製備方法及其在醫藥上的應用
HK1243414A1 (zh) 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用
HK1243999A1 (zh) 新型3-吲哚取代的衍生物、藥物組合物及使用方法
HUE057924T2 (hu) Benzazepin származék, elõállítási eljárása, gyógyászati készítmény és alkalmazása
EP3130354A4 (en) Posaconazole pharmaceutical composition and preparation method, application and pharmaceutical preparation thereof
EP3153165A4 (en) Rapamycin derivative, preparation method therefor, and pharmaceutical composition and uses thereof
HUE056175T2 (hu) Gyógyászati készítmények, elõállításuk és alkalmazásaik
IL252397A0 (en) Pharmaceutical preparations, their preparation and uses
IL290114A (en) Pharmaceutical preparations, their preparation and uses
EP3181553A4 (en) Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof
PL3106459T3 (pl) Podstawiona pirolem pochodna indolonu, sposób jej wytwarzania, zawierająca ją kompozycja i jej zastosowanie
PT3229843T (pt) Composição farmacêutica, a sua preparação e as suas utilizações
HK1214767A1 (zh) 片劑形式的藥物組合物及其製造方法
EP3078659A4 (en) 3-FURYL-2-CYANO-2-ACRYLAMIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3251672A4 (en) Pharmaceutical composition and preparation method therefor
EP3098222A4 (en) Fused acridine derivative and pharmaceutical composition, preparation method and use thereof